Dynamics of blood pressure indicators in patients with diabetes mellitus after planned percutaneous coronary intervention

Arterial hypertension (AH) is a common modifiable cardiovascular risk factor. Despite the wide choice of antihypertensive drugs, according to epidemiological studies, just over 20% of patients demonstrate effective control of hypertension. Failure to achieve the target values of blood pressure (BP) determines a high probability of developing cardiovascular events, which is also true for patients undergoing percutaneous coronary interventions (PCI). However, there is evidence that individuals who have undergone PCI show a higher percentage of achieving the target blood pressure levels. Aim of the study was to evaluate the dynamics of blood pressure indicators in patients with stable coronary artery disease (CAD) and diabetes mellitus, depending on the fact of performing PCI.

Material and methods. The study was conducted at federal state budgetary scientific institution research institute of complex issues of cardiovascular diseases as a prospective, open, not comparative. The study included 75 patients with stable CAD and type 2 diabetes who regularly received therapy for at least 1 month prior to the start of participation in this study. The majority of patients 45 (60%) are represented by males. The median age was 52.64±6.96 years. 44 patients (58.81%) had a history of myocardial infarction, and 46 patients (61.33%) had previously undergone myocardial revascularization, history of stroke had 5 patients (6.66%). All patients according to the daily blood pressure monitoring at the 1st visit had average daily blood pressure values above 130/80 mmHg. Participants were divided into 2 groups: 43 patients had indications for routine PCI at the time of inclusion in the study, 32 patients had no indications for revascularization. The groups did not have significant differences in clinical and anamnestic characteristics, and regular significant differences were noted in relation to previously undergone revascularization (46.51 and 81.25%, respectively, p=0.0022) and the SYNTAX Score (14.39±9.20 and 6.13±8.28, respectively, p=0.0001). During 4 visits (1 visit, 1 month, 3 months, 6 months), ambulatory blood pressure monitoring (ABPM) was performed using the BiPiLAB system.

Results. Initially according ABPM parameters group without the alleged PCI had greater variability in systolic blood pressure (SBP) in the daytime, higher values of mean diastolic blood pressure (DBP) at night, more time index of hypertension DBP at night. After 1 month of follow — up (for the group with PCI 1 month after the procedure), there were significant differences in the average daily SBP and DBP, the index of the time of hypertension DBP in the daytime, and the average daily SBP. Patients who underwent revascularization had lower ABPM values. The previously described differences in the night time DBP and the index of hypertension time at night were preserved. After 3 months of follow-up, significant differences were observed only in the indicators of night time SAD and DBP. At the end of the study (6 months of follow-up), the groups had differences only in the indicators of mean diastolic pressure at night.

Conclusion. Patients who underwent PCI for 1 month after the procedure have a significant tendency to normalize (compared to the group without revascularization) blood pressure indicators. However, over time, the effect «escapes». Most likely, the short-term improvement in blood pressure is due to a temporary improvement in treatment adherence after an invasive procedure.

1. Williams B, Mancia G, Spiering W, AgabitiRosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). J. Hypertens., 2018; 36 (10): 1953–2041. doi: 10.1097/HJH.0000000000001940

2. Чазова И.Е., Шестакова М.В., Жернакова Ю.В., Маркова Т.Н., Мазурина Н.В., Ежов М.В., Миронова О.Ю., Литвин А.Ю., Елфимова Е.М., Блинова Н.В., Сухарева О.Ю., Аметов А.С., Ахмеджанов Н.М., Кисляк О.А., Кухарчук В.В., Недогода С.В., Небиеридзе Д.В., Медведева И.В., Мкртумян А.М., Подзолков В.И. Российское медицинское общество по артериальной гипертонии. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями и сахарным диабетом 2-го типа. Систем. гипертензии, 2020; 17 (1): 7–45. doi: 10.26442/2075082X.2020.1.200051

3. Черняева М.С., Остроумова О.Д. Целевые уровни артериального давления у пациентов с артериальной гипертензией и ишемической болезнью сердца. Артериал. гипертензия, 2020; 26 (1): 15–26. doi: 10.18705/1607–419X2020–26–1–15–26

4. Warren J., Nanayakkara S., Andrianopoulos N., Brennan A., Dinh D., Yudi M., Clark D., Ajani A.E., Reid C.M., Selkrig L., Shaw J., Hiew C., Freeman M., Kaye D., Kingwell B.A., Dart A.M., Duffy S.J. Impact of pre-procedural blood pressure on long-term outcomes following percutaneous coronary intervention. J. Am. Coll. Cardiol., 2019; 73 (22): 2846–55. doi: 10.1016/j.jacc.2019.03.493

5. Кочергина А.М., Хорлампенко А.А. Плановое чрескожное коронарное вмешательство у пациентов с сахарным диабетом 2 типа: риски и новые способы управления. Сах. диабет, 2019; 22 (2): 151–158. doi: 10.14341/DM9827

6. World Health Organization. Adherence to longterm therapies: evidence for action. WHO Library Cataloguing-in-Publication Data, Geneva, WHO 2003. 211 р. Available at https://www.who.int/chp/knowledge/publications/adherence_report/en

7. Бунова С.С., Жернакова Н.И., Скирденко Ю.П., Николаев Н.А. Приверженность лекарственной терапии, модификации образа жизни и медицинскому сопровождению больных сердечно-сосудистыми заболеваниями. Кардиоваскуляр. терапия и профилактика, 2020; 19 (6): 2665. doi: 10.15829/1728–8800–2020–2665

8. Седых Д.Ю., Петров Г.П., Кашталап В.В. Различия приверженности к терапии у пациентов с первичным и повторным инфарктом миокарда. Комплекс. пробл. серд.-сосуд. заболеваний, 2018; 7 (4): 15–25. doi: 10.17802/2306–1278– 2018–7–4–15–25

9. Гапон Л.И., Самойлова Е.П., Бессонов И.С., Гультяева Е.П., Бердинских С.Г. Приверженность медикаментозной терапии пациентов с хронической ишемической болезнью сердца после чрескожных коронарных вмешательств. Consilium Medicum. 2020; 22 (10): 69–71. doi: 10.26442/20751753.2020.10.200253

10. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Рос. кардиол. журн., 2020; 25 (11): 4076. doi: 10.15829/29/1560–4071–2020–4076

11. Леонова В.О., Кочергина А.М., Барбараш О.Л. Клинический портрет пациента перед плановым чрескожным коронарным вмешательством в условиях реальной практики. Кардиология, 2020; 60 (4): 31–35. doi: 10.15829/29/1560–4071–2020–4076

12. Tocci G., Barbato E., Coluccia R., Modestino A., Pagliaro B., Mastromarino V., Giovannelli F., BerniA., Volpe M. Blood pressure levels at the time of percutaneous coronary revascularization and risk of coronary in-stent restenosis. Am.J. Hypertens., 2016; 29 (4): 509–518. doi: 10.1093/ajh/hpv131

13. Диспансерное наблюдение больных хроническими неинфекционными заболеваниями и пациентов с высоким риском их развития. Методические рекомендации. Ред. С.А. Бойцов, А.Г. Чучалин. М., 2014. 112 с.